 This is an open-label, dose-escalationde-escalation study of ARQ 197 administered orally in combination with gemcitabine. The study is designed to determine the safety, tolerability and maximum tolerated dose MTD or recommended Phase 2 dose RP2D of ARQ 197 when administered in combination with gemcitabine to patients with advanced solid tumors. 